SCALANCT07725939
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 23 → 26 locations
- Minor Trial sites expanded: 13 → 23 locations
- Minor Trial sites expanded: 9 → 13 locations
- Minor Study sites: 7 to 9
- Notable Eligibility criteria expanded, about 13 words
- Trial sites expanded: 4 → 7 locations
- Secondary endpoints: details revised at 6 of 6 entries
Show 2 earlier versionsHide 2 earlier versions
- Minor Study sites: 3 to 4v5
- Minor Study sites: 1 to 3v4
- Notable Recruitment opened
- Study sites: 0 to 1
- Start date changed from estimate of Jul 31, 2026 to Jul 27, 2026
- Notable Eligibility criteria expanded, about 1 wordv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Time from treatment assignment to first moderate or severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
Timeframe: Up to Week 60
Secondary (6)
Pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at 24 weeks
Annualized rate of moderate and severe AECOPD up to End of Treatment
Change from Baseline at Week 24 in St. George's Respiratory Questionnaire-COPD-specific version (SGRQ-C)
Proportion of participants with a decrease in SGRQ C total score of ≥4 points from Baseline to Week 24
Incidence of Treatment-Emergent (TE) Adverse Events (AE)
Show 1 moreShow less
Incidence of TE Serious Adverse Events (SAEs)
Arms and interventions
Galvokimig Dose 1 ArmExperimental
Participants randomly assigned to this arm will receive a predefined Galvokimig Dose.
Galvokimig Dose 2 ArmExperimental
Participants randomly assigned to this arm will receive a predefined Galvokimig Dose.
Placebo ArmPlacebo comparator
Participants randomly assigned to this arm will receive a matching Placebo.
Biologicals: Galvokimig, Placebo
Sites
26 sites in 2 countries
United States 16, China 10